GRAIL, AccessHope Collaborate to Optimize Patient and Healthcare Provider Experience for Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease
GRAIL Confirms Q2 2021 Introduction of Galleri, First-of-Kind Multi-Cancer Early Detection Blood Test
Cleveland Clinic Joins Interventional Study Using GRAIL’s Multi-Cancer Early Detection Test to Help Guide Clinical Care
